DANAHER CORP /DE/
At today's price, DANAHER CORP /DE/ (DHR) is priced for today's economics sustained for ~5.6 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Danaher is a life-sciences and diagnostics conglomerate built on recurring revenue: its bioprocessing tools, diagnostics, and consumables sell over and over to drugmakers and labs, and the prized bioprocessing business just posted its first order growth in nearly two years, up more than 30% [Source: Q1 2026 results, April 2026]. • The biggest risk is China and policy: a large share of growth comes from high-growth markets, and Chinese volume-based procurement reforms plus a soft respiratory se
Is DHR overvalued? See what's priced in →
2,109 institutional managers reported holding DHR in 13F filings for the quarter ended 2026-03-31. Together they hold about 77% of the company; the top 10 hold 34%. 134 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 11.5M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
DHR has cut its share count 12.2% over the past five years, spending $9.07B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 12 years straight. Cash returned over the past three years: $2.27B in dividends and $9.07B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at DHR over the trailing three years. Absence is a fact about the company, not a signal. 25 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
DHR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-26 | +2.7% | -6.6% |
| 2023-10-25 | -5.6% | +20.9% |
| 2024-02-22 | +3.1% | -2.7% |
| 2024-04-24 | +6.1% | +1.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
DHR's latest 8-K filings: 2026-06-03 (items 2.03, 8.01); 2026-05-07 (items 5.02, 5.07, 9.01); 2026-04-29 (items 1.01, 8.01, 9.01); 2026-04-21 (items 2.02, 9.01); 2026-04-17 (items 1.01, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.